” With the advancement of ultrasensitive blood-based protein detection innovation, we have established an easy, noninvasive, and accurate diagnostic service for advertisement, which will considerably assist in population-scale screening and staging of the illness,” stated Prof. Nancy Ip, Morningside Professor of Life Science and the Director of the State Key Laboratory of Molecular Neuroscience at HKUST
The work was performed in partnership with researchers at University College London and clinicians in regional health centers consisting of the Prince of Wales Hospital and Queen Elizabeth Hospital. The discovery was made utilizing the proximity extension assay (PEA)– an innovative ultrasensitive and high-throughput protein measurement technology, to analyze the levels of over 1,000 proteins in the plasma of advertisement clients in Hong Kong.
Using the blue gadget (visualized) that carries out the ultrasensitive proximity extension assay innovation, Prof. Ip and her group established a blood test for early detection and screening of Alzheimers illness from Chinese patient data, with a precision level of over 96%. Credit: HKUST.
As the most comprehensive study of blood proteins in advertisement clients to date, the work has recently been released in Alzheimers & & Dementia: The Journal of the Alzheimers Association, and has likewise been featured and actively discussed on various academic exchange platforms on advertisement research such as Alzforum.
AD, which affects over 50 million people worldwide, includes the dysfunction and loss of brain cells. Its symptoms include progressive memory loss along with impaired motion, thinking, and judgment. While clients often only seek medical attention and are diagnosed when they have memory issues, AD affects the brain at least 10-20 years before symptoms appear.
Reference: “Large-scale plasma proteomic profiling identifies a high-performance biomarker panel for Alzheimers illness screening and staging” by Yuanbing Jiang, Xiaopu Zhou, Fanny C. Ip, Philip Chan, Yu Chen, Nicole C.H. Lai, Kit Cheung, Ronnie M.N. Lo, Estella P.S. Tong, Bonnie W.Y. Wong, Andrew L.T. Chan, Vincent C.T. Mok, Timothy C.Y. Kwok, Kin Y. Mok, John Hardy, Henrik Zetterberg, Amy K.Y. Fu and Nancy Y. Ip, 25 May 2021,. DOI: 10.1002/ alz.12369.
HKUSTs Vice-President (Research and Development) Prof. Nancy IP (Middle) and her research employee– including doctoral trainee Mr. Jason JIANG Yuanbing (second left) who is the first author of this research study paper. Credit: HKUST
A worldwide research group led by HKUST has established a easy but robust blood test from Chinese client information for early detection and screening of Alzheimers illness (AD) for the very first time, with an accuracy level of over 96%.
Currently, medical professionals generally rely on cognitive tests to identify a person with AD. Medical assessment, brain imaging and lumbar puncture are the two most frequently used medical procedures to spot modifications in the brain caused by AD. However, these techniques are expensive, intrusive, and frequently unavailable in lots of countries.
The research study team determined 19 plasma hub proteins (indicated as yellow dots in the figure) in advertisement patients, which are irregular compared to healthy individuals. Credit: HKUST
Now, a group led by Prof. Nancy IP, Vice-President for Research and Development at HKUST, has identified 19 out of the 429 plasma proteins related to AD to form a biomarker panel agent of an “advertisement signature” in the blood. Based upon this panel, the group has established a scoring system that identifies AD patients from healthy people with more than 96% precision. This system can likewise distinguish amongst the early, intermediate, and late stages of AD, and can be utilized to keep track of the progression of the illness gradually. These interesting findings have actually resulted in the development of a high-performance, blood-based test for advertisement, and may also pave the method to unique healing treatments for the disease.
While patients frequently just seek medical attention and are detected when they have memory problems, AD affects the brain at least 10-20 years before signs appear.
Now, a group led by Prof. Nancy IP, Vice-President for Research and Development at HKUST, has identified 19 out of the 429 plasma proteins associated with AD to form a biomarker panel agent of an “AD signature” in the blood. Based on this panel, the group has established a scoring system that differentiates Advertisement clients from healthy individuals with more than 96% accuracy. These exciting findings have led to the development of a high-performance, blood-based test for Advertisement, and may likewise pave the way to unique healing treatments for the illness.
